VCYT · Veracyte, Inc. · Executive Compensation
$50.29
+1.29 (+2.63%)
At close · Nov 3
Return incl. dividend (before tax)
Q2 2026 earnings call transcript
Market Cap
$4.04B
Shares
80.39M
Volume · Nov 3
1.08M
Avg daily vol (3M)
1.3M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Marc Stapley | Chief Executive Officer | $7,421,877 |
| John Leite | Global Chief Commercial Officer | $3,202,810 |
| Rebecca Chambers | Chief Financial Officer | $2,875,554 |
| Annie McGuire | General Counsel and Head of Market Access | $2,793,104 |
| Phillip G. Febbo | Chief Scientific Officer and Chief Medical Officer | $2,500,972 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Marc Stapley | Chief Executive Officer | $6,816,368 |
| Rebecca Chambers | Chief Financial Officer | $3,645,346 |
| John Leite | Global Chief Commercial Officer | $3,093,951 |
| Annie McGuire | General Counsel and Chief People Officer | $3,090,848 |
| Phillip G. Febbo | Chief Scientific and Chief Medical Officer | $2,789,661 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Marc Stapley | Chief Executive Officer | $7,184,634 |
| Phillip G. Febbo | Chief Scientific and Chief Medical Officer | $3,787,041 |
| Rebecca Chambers | Chief Financial Officer | $2,778,584 |
| Annie McGuire | General Counsel and Chief People Officer | $2,481,118 |
| John Leite | Global Chief Commercial Officer | $1,924,469 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Marc Stapley | Chief Executive Officer | $4,935,422 |
| Tina Nova | General Manager, Decipher Urologic Cancers The amounts in this column represent bonuses awarded to Ms. Kennedy at the discretion of our Board of Directors above the amounts earned by meeting the performance measures established under our 2020 Bonus Plan and a sign-on bonus of 100,000 paid to Ms. Chambers in 2021. Amounts represent the aggregate fair value of the awards computed as of the grant date of each award in accordance with Topic 718 for financial reporting purposes, rather than amounts paid to or realized by the named individual. Our assumptions with respect to the calculation of these values are set forth in the Notes to Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2022. There can be no assurance that option awards will be exercised or that RSUs will settle (in which case no value will be realized by the individual) or that the value on exercise of options or settlement of RSUs will approximate the fair value as computed in accordance with Topic 718. We computed the grant date fair value of PSU awards based on our achievement of the PSU awards' performance conditions at 100% of target. If the PSUs were instead valued based on the maximum outcome of the applicable performance condition (i.e., based on maximum level performance), the total amount for the PSU awards reported in this column for 2022 would increase as follows: Mr. Stapley from 735,533 to 919,417, Ms. Chambers from 269,671 to 337,089, Ms. Kennedy from 551,780 to 689,725, and Ms. Nova from 735,663 to 919,579. The amounts reported in the Non-Equity Incentive Plan Compensation column for 2022 represent annual cash bonuses paid to the Named Executive Officers as described in “—Compensation Discussion and Analysis—2022 Annual Cash Incentives.” Other income includes matching contributions to 401(k) plans in an amount up to 3,000 per year for 2022 and 2021 and 2,000 per year for 2020. Other income for Ms. McGuire also includes assistance with housing expenses and tax gross-up paid for such expenses, pursuant to the terms of her employment agreement, totaling 74,765 for 2022. Ms. Kennedy departed from our company on December 31, 2022 and her other income also includes 275,000 of annual performance bonus, 250,000 of severance, 100,000 cash bonus, and 42,998 of COBRA payments. Ms. Kennedy departed from the company effective December 31, 2022. | $4,598,529 |
| Giulia Kennedy | Former Global Chief Scientific and Chief Medical Officer | $4,533,563 |
| Rebecca Chambers | Chief Financial Officer | $3,322,756 |
| Annie McGuire | General Counsel and Chief People Officer | $2,447,055 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Marc Stapley | Chief Executive Officer | $5,741,940 |
| Bonnie Anderson | Co-Founder and Executive Chair | $4,518,093 |
| Bonnie H. Anderson | Co-Founder and Executive Chair | $4,518,093 |
| Rebecca Chambers | Chief Financial Officer | $3,382,037 |
| Keith Kennedy | Chief Operating Officer and Chief Financial Officer The amounts in this column represent bonuses awarded at the discretion of our Board of Directors above the amounts earned by meeting the performance measures established under our 2021 Bonus Plan. For more information see "—Compensation Discussion and Analysis-2021 Bonus Plan Awards." Amounts represent the aggregate fair value of the awards computed as of the grant date of each award in accordance with Topic 718 for financial reporting purposes, rather than amounts paid to or realized by the named individual. Our assumptions with respect to the calculation of these values are set forth in the Notes to Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2021. There can be no assurance that option awards will be exercised or that RSUs will settle (in which case no value will be realized by the individual) or that the value on exercise of options or settlement of RSUs will approximate the fair value as computed in accordance with Topic 718. We computed the grant date fair value of PSU awards based on our achievement of the PSU awards' performance conditions at 100% of target. Other income includes matching contributions to 401(k) plans in an amount up to 3,000 per year for 2021 and 2,000 per year for 2020 and 2019. Other income for Ms. Chambers includes a sign-on bonus of 100,000. Other compensation includes severance and COBRA payments in the amount of 238,500. Other income for Mr. Kennedy also includes assistance with travel and living expenses associated with his commuting to our executive offices in South San Francisco, California as described in footnote below. Pursuant to the terms of his employment agreement, Mr. Kennedy was entitled to travel and living expense assistance in connection with his commuting to our executive offices in South San Francisco, California. In 2020 and 2019, these amounts totaled 146,357 and, 185,466, respectively, for reimbursed expenses for airline travel, parking, transportation and related travel incidentals, and living expense and tax gross-up paid for such expenses. Mr. Kennedy retired from our company, effective May 15, 2021. | $2,654,814 |
| Giulia Kennedy | Former Global Chief Scientific and Chief Medical Officer | $2,636,699 |
| Jane Alley | Vice President, Accounting | $1,288,216 |
| James Erlinger III | Former Executive Vice President and General Counsel | $1,215,753 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Bonnie H. Anderson | Co-Founder and Executive Chair | $4,571,345 |
| Bonnie Anderson | Co-Founder and Executive Chair | $4,571,345 |
| James Erlinger III | Former Executive Vice President and General Counsel | $3,118,425 |
| Keith Kennedy | Chief Operating Officer and Chief Financial Officer The amounts in this column represent bonuses awarded at the discretion of our Board of Directors above the amounts earned by meeting the performance measures established under our 2021 Bonus Plan. For more information see "—Compensation Discussion and Analysis-2021 Bonus Plan Awards." Amounts represent the aggregate fair value of the awards computed as of the grant date of each award in accordance with Topic 718 for financial reporting purposes, rather than amounts paid to or realized by the named individual. Our assumptions with respect to the calculation of these values are set forth in the Notes to Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2021. There can be no assurance that option awards will be exercised or that RSUs will settle (in which case no value will be realized by the individual) or that the value on exercise of options or settlement of RSUs will approximate the fair value as computed in accordance with Topic 718. We computed the grant date fair value of PSU awards based on our achievement of the PSU awards' performance conditions at 100% of target. Other income includes matching contributions to 401(k) plans in an amount up to 3,000 per year for 2021 and 2,000 per year for 2020 and 2019. Other income for Ms. Chambers includes a sign-on bonus of 100,000. Other compensation includes severance and COBRA payments in the amount of 238,500. Other income for Mr. Kennedy also includes assistance with travel and living expenses associated with his commuting to our executive offices in South San Francisco, California as described in footnote below. Pursuant to the terms of his employment agreement, Mr. Kennedy was entitled to travel and living expense assistance in connection with his commuting to our executive offices in South San Francisco, California. In 2020 and 2019, these amounts totaled 146,357 and, 185,466, respectively, for reimbursed expenses for airline travel, parking, transportation and related travel incidentals, and living expense and tax gross-up paid for such expenses. Mr. Kennedy retired from our company, effective May 15, 2021. | $2,025,917 |
| Giulia Kennedy | Former Global Chief Scientific and Chief Medical Officer | $1,870,560 |
| John Hanna | Chief Commercial Officer | $1,785,853 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Bonnie H. Anderson | Co-Founder and Executive Chair | $4,161,963 |
| Bonnie Anderson | Co-Founder and Executive Chair | $4,161,963 |
| Keith Kennedy | Chief Operating Officer and Chief Financial Officer The amounts in this column represent bonuses awarded at the discretion of our Board of Directors above the amounts earned by meeting the performance measures established under our 2021 Bonus Plan. For more information see "—Compensation Discussion and Analysis-2021 Bonus Plan Awards." Amounts represent the aggregate fair value of the awards computed as of the grant date of each award in accordance with Topic 718 for financial reporting purposes, rather than amounts paid to or realized by the named individual. Our assumptions with respect to the calculation of these values are set forth in the Notes to Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2021. There can be no assurance that option awards will be exercised or that RSUs will settle (in which case no value will be realized by the individual) or that the value on exercise of options or settlement of RSUs will approximate the fair value as computed in accordance with Topic 718. We computed the grant date fair value of PSU awards based on our achievement of the PSU awards' performance conditions at 100% of target. Other income includes matching contributions to 401(k) plans in an amount up to 3,000 per year for 2021 and 2,000 per year for 2020 and 2019. Other income for Ms. Chambers includes a sign-on bonus of 100,000. Other compensation includes severance and COBRA payments in the amount of 238,500. Other income for Mr. Kennedy also includes assistance with travel and living expenses associated with his commuting to our executive offices in South San Francisco, California as described in footnote below. Pursuant to the terms of his employment agreement, Mr. Kennedy was entitled to travel and living expense assistance in connection with his commuting to our executive offices in South San Francisco, California. In 2020 and 2019, these amounts totaled 146,357 and, 185,466, respectively, for reimbursed expenses for airline travel, parking, transportation and related travel incidentals, and living expense and tax gross-up paid for such expenses. Mr. Kennedy retired from our company, effective May 15, 2021. | $2,773,676 |
| Giulia Kennedy | Global Chief Scientific and Chief Medical Officer | $2,124,410 |
| John Hanna | Chief Commercial Officer | $2,030,010 |
| Christopher Hall | The amounts in this column represent bonuses awarded at the discretion of our board of directors above the amounts earned by meeting the performance measures established under our 2019 Bonus Plan. For more information see"-Compensation Discussion and Analysis-2019 Bonus Plan Awards.". Amounts represent the aggregate fair value of the awards computed as of the grant date of each award in accordance with Topic 718 for financial reporting purposes, rather than amounts paid to or realized by the named individual. Our assumptions with respect to the calculation of these values are set forth in the Notes to Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2018. There can be no assurance that option awards will be exercised or that RSUs or PSUs will settle (in which case no value will be realized by the individual) or that the value on exercise of options or settlement of RSUs or PSUs will approximate the fair value as computed in accordance with Topic 718. We computed the grant date fair value of PSU awards based on our achievement of the PSU awards' performance conditions at 100% of target, which was the probable outcome of the performance conditions as of December 31, 2018. The PSUs do not have staggered levels of achievement. Other income includes matching contributions to 401(k) plans in an amount up to 2,000 per year. Other income for Mr. Kennedy also includes assistance with travel and living expenses associated with his commuting to our executive offices in South San Francisco, California as described in footnote below. Pursuant to the terms of his employment agreement, Mr. Kennedy is entitled to travel and living expense assistance in connection with his commuting to our executive offices in South San Francisco, California. In 2019, 2018 and 2017, these amounts totaled 185,466, 200,899 and 197,709, respectively, for reimbursed expenses for airline travel, parking, transportation and related travel incidentals, and living expense and tax gross-up paid for such expenses. | $700,674 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Bonnie Anderson | Chairman and Chief Executive Officer | $2,831,240 |
| Bonnie H. Anderson | Chairman and Chief Executive Officer | $2,831,240 |
| Christopher Hall | The amounts in this column represent bonuses awarded at the discretion of our board of directors above the amounts earned by meeting the performance measures established under our 2019 Bonus Plan. For more information see"-Compensation Discussion and Analysis-2019 Bonus Plan Awards.". Amounts represent the aggregate fair value of the awards computed as of the grant date of each award in accordance with Topic 718 for financial reporting purposes, rather than amounts paid to or realized by the named individual. Our assumptions with respect to the calculation of these values are set forth in the Notes to Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2018. There can be no assurance that option awards will be exercised or that RSUs or PSUs will settle (in which case no value will be realized by the individual) or that the value on exercise of options or settlement of RSUs or PSUs will approximate the fair value as computed in accordance with Topic 718. We computed the grant date fair value of PSU awards based on our achievement of the PSU awards' performance conditions at 100% of target, which was the probable outcome of the performance conditions as of December 31, 2018. The PSUs do not have staggered levels of achievement. Other income includes matching contributions to 401(k) plans in an amount up to 2,000 per year. Other income for Mr. Kennedy also includes assistance with travel and living expenses associated with his commuting to our executive offices in South San Francisco, California as described in footnote below. Pursuant to the terms of his employment agreement, Mr. Kennedy is entitled to travel and living expense assistance in connection with his commuting to our executive offices in South San Francisco, California. In 2019, 2018 and 2017, these amounts totaled 185,466, 200,899 and 197,709, respectively, for reimbursed expenses for airline travel, parking, transportation and related travel incidentals, and living expense and tax gross-up paid for such expenses. | $1,578,415 |
| Keith Kennedy | Chief Operating Officer and Chief Financial Officer | $1,466,109 |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| Bonnie H. Anderson | Chairman and Chief Executive Officer | $2,213,128 |
| Bonnie Anderson | Chairman and Chief Executive Officer | $2,213,128 |
| Christopher Hall | The amounts in this column represent bonuses awarded at the discretion of our board of directors above the amounts earned by meeting the performance measures established under our 2019 Bonus Plan. For more information see"-Compensation Discussion and Analysis-2019 Bonus Plan Awards.". Amounts represent the aggregate fair value of the awards computed as of the grant date of each award in accordance with Topic 718 for financial reporting purposes, rather than amounts paid to or realized by the named individual. Our assumptions with respect to the calculation of these values are set forth in the Notes to Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2018. There can be no assurance that option awards will be exercised or that RSUs or PSUs will settle (in which case no value will be realized by the individual) or that the value on exercise of options or settlement of RSUs or PSUs will approximate the fair value as computed in accordance with Topic 718. We computed the grant date fair value of PSU awards based on our achievement of the PSU awards' performance conditions at 100% of target, which was the probable outcome of the performance conditions as of December 31, 2018. The PSUs do not have staggered levels of achievement. Other income includes matching contributions to 401(k) plans in an amount up to 2,000 per year. Other income for Mr. Kennedy also includes assistance with travel and living expenses associated with his commuting to our executive offices in South San Francisco, California as described in footnote below. Pursuant to the terms of his employment agreement, Mr. Kennedy is entitled to travel and living expense assistance in connection with his commuting to our executive offices in South San Francisco, California. In 2019, 2018 and 2017, these amounts totaled 185,466, 200,899 and 197,709, respectively, for reimbursed expenses for airline travel, parking, transportation and related travel incidentals, and living expense and tax gross-up paid for such expenses. | $1,084,004 |
| Keith Kennedy | Chief Operating Officer, Chief Financial Officer and Secretary | $792,685 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Marc Stapley | director | Appointed | 2026-06-11 |
| Brent Shafer | director | Appointed | 2026-06-11 |
| Evan Jones | director | Appointed | 2026-06-11 |
| Tom Miller | director | Appointed | 2026-06-11 |
| Karin Eastham | director | Appointed | 2026-06-11 |
| Robert S. Epstein | director | Appointed | 2026-06-11 |
| Jens Holstein | director | Appointed | 2026-06-11 |
| Muna Bhanji | director | Appointed | 2026-06-11 |
| Eliav Barr | director | Appointed | 2026-06-11 |
| Dr. Kevin Haas | Chief Development and Technology Officer | Appointed | 2026-03-16 |
| Marc Stapley | director | Appointed | 2025-06-18 |
| Brent Shafer | director | Appointed | 2025-06-18 |
| Jens Holstein | director | Appointed | 2025-06-18 |
| Tom Miller | director | Appointed | 2025-06-18 |
| Karin Eastham | director | Appointed | 2025-06-18 |
| Muna Bhanji | director | Appointed | 2025-06-18 |
| Eliav Barr | director | Appointed | 2025-06-18 |
| Brent Shafer | directors of the Company | Appointed | 2024-09-04 |
| Tom Miller, Ph.D. | directors of the Company | Appointed | 2024-09-04 |
| Marc Stapley | director | Appointed | 2024-06-13 |
| Muna Bhanji | director | Appointed | 2024-06-13 |
| Tina S. Nova, Ph.D. | General Manager, Urological Cancers | Resigned | 2023-08-08 |
| Evan Jones | Class I Director | Appointed | 2023-06-09 |
| Robert S. Epstein | Class I Director | Appointed | 2023-06-09 |
| Giulia C. Kennedy, Ph.D | Global Chief Scientific Officer and Chief Medical Officer | Terminated | 2022-12-14 |
Leadership
- Marc Stapley CEO, Board Member
- Bonnie H. Anderson Chairman
- Rebecca Chambers CFO
- Christopher Hall COO
- Dr. Kevin Haas CTO
- Annie McGuire General Counsel
- Beverly Jane Alley Chief Accounting Officer
- Jonathan Wygant Chief Accounting Officer
- Brent Shafer Board Member
- Eliav Barr, M.D. Board Member
- Tom Miller Board Member
- Tom Miller, Ph.D. Board Member
Key facts
CIK
1384101
CUSIP
92337F107
13F (30d)
113 filings
102 filers
Visit website
Investor relations